OncoMatch/Clinical Trials/NCT07024173
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Is NCT07024173 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for locally advanced breast cancer.
Treatment: HRS-8080 Tablet · Fulvestrant · Exemestane tablets · Everolimus Tablets · Anastrozole Tablets · Letrozole Tablets — This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: endocrine therapy
Lab requirements
Blood counts
The functional level of the organs must meet the requirements.
Kidney function
The functional level of the organs must meet the requirements.
Liver function
The functional level of the organs must meet the requirements.
The functional level of the organs must meet the requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07024173 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received endocrine therapy.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages